Anti-CD45RO 抗体 [UCH-L1] (ab23)
製品の概要
-
製品名Anti-CD45RO antibody [UCH-L1]
CD45RO 一次抗体 製品一覧 -
製品の詳細Mouse monoclonal [UCH-L1] to CD45RO
-
由来種Mouse
-
アプリケーション適用あり: Flow Cyt, IP, WB, IHC-P, IHC-Frmore details
-
種交差性交差種: Human
-
免疫原
Cultured T cells from an IL-2-dependent T-cell line (CA1) prepared from human peripheral blood activated with influenza virus.
-
ポジティブ･コントロール
- IHC-P: Human tonsil tissue. WB: Human tonsil and thymus tissue lysate. Flow Cytometry: HeLa cells.
製品の特性
-
製品の状態Liquid
-
保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
バッファーConstituent: PBS
-
Concentration information loading... -
精製度Protein A purified
-
ポリ/モノモノクローナル
-
クローン名UCH-L1
-
ミエローマP3-NS1/1-Ag4-1
-
アイソタイプIgG2a
-
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
アプリケーション
Our Abpromise guarantee covers the use of ab23 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Flow Cyt | Use at an assay dependent concentration. ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
|
| IP | Use at an assay dependent concentration. | |
| WB | Use a concentration of 5 µg/ml. Detects a band of approximately 180 kDa (predicted molecular weight: 131 kDa). | |
| IHC-P | Use at an assay dependent concentration. | |
| IHC-Fr | Use at an assay dependent concentration. |
ターゲット情報
-
機能Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity.
-
関連疾患Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. -
配列類似性Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains. -
ドメインThe first PTPase domain interacts with SKAP1.
-
翻訳後修飾Heavily N- and O-glycosylated.
-
細胞内局在Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
-
参照データベース
- Entrez Gene: 5788 Human
- Omim: 151460 Human
- SwissProt: P08575 Human
- Unigene: 654514 Human
-
別名
- B220 antibody
- CD45 antibody
- cd45 antigen antibody
see all
画像
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45RO antibody [UCH-L1] (ab23)](https://www.abcam.co.jp/ps/products/0/ab23/Images/CD45RO-Primary-antibodies-ab23-1.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45RO antibody [UCH-L1] (ab23)ab23 (1 µg/ml) staining CD45RO in human tonsil.
Sections were stained using an automated system (DAKO Autostainer Plus ), at room temperature: sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffers citrate pH 6.1. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with hematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required. -
![Western blot - Anti-CD45RO antibody [UCH-L1] (ab23)](https://www.abcam.co.jp/ps/products/0/ab23/Images/CD45RO-Primary-antibodies-ab23-5.jpg)
Western blot - Anti-CD45RO antibody [UCH-L1] (ab23)All lanes : Anti-CD45RO antibody [UCH-L1] (ab23) at 5 µg/ml
Lane 1 : Human tonsil normal tissue lysate - total protein (ab29615)
Lane 2 : Human thymus tissue lysate - total protein (ab30146)
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 131 kDa
Observed band size: 180 kDa why is the actual band size different from the predicted?
Additional bands at: 120 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 8 minutes
CD45RO contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
データシートおよび資料
プロトコール
参考文献
This product has been referenced in:
- Wu X et al. Folic acid reverses uric acid crystal-induced surface OAT1 internalization by inhibiting RhoA activity in uric acid nephropathy. Mol Med Rep 13:2385-92 (2016). Read more (PubMed: 26846716) »
- Zhang P et al. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer. FEBS Lett 589:2248-56 (2015). IHC-P ; Human . Read more (PubMed: 26149216) »
